A Phase 1 Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs Cetuximab (Primary) ; Selumetinib (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 14 Dec 2015 Results published in the Investigational New Drugs
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.